Home » Newsletters » BioWorld Science

BioWorld Science

June 16, 1998

View Archived Issues

Yamanouchi updates R&D pipeline

AVI Biopharma offers oncology products for licensing

Agouron and Immune Response collaborate on the commercialization of Remune

Favorable phase II results reported for Optison in perfusion studies

Tanabe's selective SGLT inhibitor shows potential for diabetes Rx

NOX-101 protects against endothelial dysfunction in diabetic rats

Vertex makes cancer drug available for licensing

Insulin sensitizers profiled at ADA meeting

Targeted Genetics' E1A gene therapy downregulates HER-2/neu oncogene in phase I

Head-to-head comparison of the antihypertensive effects of an NEP/ACE inhibitor and an ACE inhibitor

GH secretatogues in development at Merck & Co.

Biogen seeks partners to continue development of gelsolin

Substituted carbapenems active against Gram-positive bacteria

Tricyclic compounds inhibiting abnormal cell growth discovered at Schering-Plough

Shiseido presents antisecretory/antibacterial agents for ulcers

New cholinergic muscarinic receptor-binding compounds from AHP

Nippon Suisan isolates the first trisubstituted alkyl phenol antioxidant from a fungal source

DRF-2189, a new insulin-sensitizing thiazolidinedione derivative from Dr. Reddy

Taisho presents the topoisomerase II inhibitor NCA-0424

Eprosartan: overview of clinical pharmacology

Results from antiangiogenic cancer gene therapy reported

Positive FDA preliminary review of Cenestin NDA

Alexion presents antidiabetic fusion protein at ADA meeting

CytoTherapeutics and Astra resume phase IIb clinical trial of pain control implant

DiavaX potential for vaccination against diabetes shown in preclinical models

ICN acquires pharmaceutical company in Czech Republic

TH-9506 achieves positive phase I results

Eisai launches monteplase in first market

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...